Posts Tagged ‘biotechnology’

A couple weeks back, I launched a brief blog series about assessing and mitigating risk with regulated IT systems. This week’s post will cover the first part in a four-part approach you can use to do just that: assess and mitigate risk. Part One: System Regulated Status The first step is to determine whether a […]

Just last week, the house voted to repeal Obamacare, and much has already been covered in articles readily available on the internet. But the Senate has already stated they will write up new legislation that will take into consideration the House bill. No timeline for the Senate to produce its new legislation has been set, […]

One of the key issues and perspectives we outlined in our recent State of the Life Sciences Industry guide was President Trump’s intention to reform the Food and Drug Administration (FDA) through the elimination or significant modification of regulations. Part of his recipe for reforming the FDA included bringing in a new head of the […]

Happy May Day! Now that May is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in April – they’re ranked in order of popularity, with number one being the most viewed piece. My Colleagues […]

Because Siebel Innovation Pack (IP) 2016 was such a significant departure from previous Siebel versions, our clinical operations team devoted much of last year to beta testing it, helping Oracle identify and iron out the kinks. Now that we have finished our assessment of the risks and rewards of upgrading Siebel Clinical to IP2016, we […]

The industry is all a-buzz with digital engagement initiatives for patients, but let’s not forget about clinical subjects and even site personnel. They’re technology consumers, just like the rest of us, and they crave clinical trials that are simple, easy, convenient, and engaging. As an advocate for sites and subjects, Perficient just published a guide […]

Last month, Duke University and the FDA released the results of a jointly conducted study on principal investigator (PI) retention. The study was released early online, but the print version is being published in June in the journal of Contemporary Clinical Trials Communications, published by Elsevier. The purpose of the study was two-fold: 1) to […]

Last year’s presidential election invoked a great deal of angst in the pharmaceutical industry, with the cost of drugs taking center stage for a good portion of some candidates’ campaigns. While the things candidates said they would do could very well be different from what they might actually do, their words and records were enough […]

Fortune just released their list of the 100 best companies to work for in America. The survey, which was compiled by Great Places to Work, generated feedback from over 230,000 individuals. The data collected and analyzed took into consideration a variety of aspects that have the potential to influence people’s feelings towards their workplace, including […]

There are plenty of articles out there about how the pharmaceutical industry may be affected by Donald Trump’s presidency. The problem is that nobody exactly knows how things are going to pan out over the next few years. When it comes to health insurance, the price of drugs, and the quality of providers across the entire health […]

My colleague, Chris Bangma, published a blog post last week that touches on how IBM Maximo, a comprehensive asset management system for managing physical assets, can comply with the FDA’s 21 CFR Part 11 regulation. In particular, he highlights three key areas of the rule that governs the use of electronic records and electronic signatures […]

Subject screening adds significant cost to a trial, so it’s an ideal process to try to streamline. Subjects who don’t meet eligibility requirements ultimately lower the efficiency and ROI of a trial, since time and money was spent on those assessments. The screening process is one area that presents an opportunity for cost-savings, whether it […]